| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.1 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.088 | 0.1 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.067 | 0.1 |